Skip to main content

Table 1 Patient demographics

From: Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

  QOL population Cost population FAS population
  Taxane S-1 Taxane S-1 Taxane S-1
  N = 175 N = 208 N = 70 N = 76 N = 286 N = 306
Median age 57.0 59.0 58.0 59.0 58.5 59.0
Hormone receptor status
 ER-positive, PgR-positive, or both 127 (72.6) 149 (71.6) 50 (71.4) 54 (71.1) 212 (74.1) 223 (72.9)
 ER-negative and PgR-negative 45 (25.7) 53 (25.5) 18 (25.7) 20 (26.3) 71 (24.8) 76 (24.8)
 Unknown 3 (1.7) 6 (2.9) 2 (2.9) 2 (2.6) 3 (1.0) 7 (2.3)
HER2 status
 Negative 162 (92.6) 192 (92.3) 64 (91.4) 71 (93.4) 264 (92.3) 282 (92.2)
 Unknown 13 (7.4) 16 (7.7) 6 (8.6) 5 (6.6) 22 (7.7) 24 (7.8)
Components of (neo)adjuvant treatment
 Oral fluoropyrimidine 26 (14.9) 22 (10.6) 9 (12.9) 10 (13.2) 39 (13.6) 35 (11.4)
 Taxane 49 (28.0) 61 (29.3) 19 (27.1) 24 (31.6) 80 (28.0) 80 (26.1)
 Endocrine therapy 100 (57.1) 111 (53.4) 44 (62.9) 45 (59.2) 170 (59.4) 169 (55.2)
Disease-free interval
  ≤ 2 years 34 (19.4) 41 (19.7) 14 (20.0) 19 (25.0) 57 (19.9) 60 (19.6)
 2–5 years 52 (29.7) 66 (31.7) 23 (32.9) 22 (28.9) 98 (34.3) 103 (33.6)
  ≥ 5 years 58 (33.1) 67 (32.2) 24 (34.3) 25 (32.9) 86 (30.0) 94 (30.7)
 Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
 No surgery 31 (17.7) 34 (16.3) 9 (12.9) 10 (13.2) 45 (15.7) 47 (15.4)
Liver metastasis
 Yes 61 (34.9) 78 (37.5) 20 (28.6) 27 (35.5) 96 (33.6) 103 (33.7)
 No 114 (65.1) 130 (62.5) 50 (71.4) 49 (64.5) 190 (66.4) 203 (66.3)